An observational study in Ataxia Telangiectasia, sponsored by Insmed Incorporated. Recruiting at 5 sites in 2 countries. Open to participants aged 1 Year to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Insmed Incorporated · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Ataxia Telangiectasia with a site in United States — 3 open to participants now, 5 under way, 1 of them phase 3. Ataxia Telangiectasia · United States.
Among the 17 studies in Ataxia Telangiectasia with a site in United States, this one is one of 2 that started in 2026, is one of 4 observational ones, and was the 17th registered.
43 studies on the registry are indexed under Ataxia Telangiectasia; 8 are open to participants now.
Browse Ataxia Telangiectasia studies →3 of the 17 studies in Ataxia Telangiectasia with a site in United States are open now. Recruiting first, the newest first:
Timothy Yu · Sites in United States
Ages 0–17
Sanford Health · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Ataxia Telangiectasia studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 1 Year to 10 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 4
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 69 is close to the median of 63 across 13 observational studies indexed under Ataxia Telangiectasia.
Median enrollment 20 across the 13 interventional studies, 193 across the 4 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 17 have an industry lead sponsor. The 10 most frequent:
Insmed Incorporated is the lead sponsor of 51 studies on the registry; 9 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 8 (29%) have results posted.
Insmed Incorporated has 1 study filed under Ataxia Telangiectasia — fewer than ten, so there is no comparison to draw.
1 of the studies in Ataxia Telangiectasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692596H. Lee Moffitt Cancer Center and Research InstituteThe Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Ataxia Telangiectasia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the natural history of AT symptoms and disease progression over time in children aged 1 to 10 years old diagnosed with classic AT.
Participants who meet all the inclusion criteria and none of the exclusion criteria will be eligible for inclusion in their respective cohort as appropriate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria for the Healthy Comparator Cohort:
Exclusion Criteria for the AT Cohort:
Exclusion Criteria for the Healthy Comparator Cohort:
Note: Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with confirmed AT at screening visit will be enrolled and followed for 24 months.
Participants without diagnosis of AT at screening visit will be enrolled and followed for 24 months.
AT Cohort: Change From Baseline in AT Neurological Examination Scale Toolkit (A-TNEST) Score
Time frame: Baseline up to Month 24
AT Cohort: Change From Baseline in International Cooperative Ataxia Rating Scale (ICARS) Score
Time frame: Baseline up to Month 24
Change From Baseline in Height
Time frame: Baseline up to Month 24
Change From Baseline in Weight
Time frame: Baseline up to Month 24
Percentage of Participants Achieving Pre-defined Developmental Goals as Assessed by Denver Developmental Screening Test (DDST-II)
Time frame: Up to Month 24
AT Cohort: Change From Baseline in Pediatric Quality of Life Inventory (Peds QL) Score Measured by the Pediatric Quality of Life Inventory
Time frame: Baseline up to Month 24
Change From Baseline in Motor Activity Assessed by Wearable Device
A wearable accelerometer will capture participant's movements during their everyday activities at home. These data will be processed using specific algorithms to generate measurements that include total sedentary time and time spent in light, moderate and vigorous activity.
Time frame: Baseline up to Month 24
Change From Baseline in Arm Function Assessed by Hevelius Test
Time frame: Baseline up to Month 24
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for May 2029, 35 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.